A type of medication known as non-nucleoside reverse transcriptase inhibitors includes efavirenz. EFV is used to treat AIDS along with other anti-retroviral medications. It functions by reducing the level of blood-borne HIV infection. Acquired immunodeficiency syndrome is not cured, however, it does prevent catastrophic infections like TB and HIV-related cancer. In antiretroviral therapy regimens, it is administered in conjunction with other inhibitors. The most important kind of treatment for persons with human immunodeficiency virus infection is adequate antiretroviral therapy since it increases survival and guards against future infections. The task of the analysts in creating and validating such pharmaceutical substances is difficult as a result.The review that has been presented consequently completely covers the efavirenz analytical results that have been gathered from a number of sources, including Scopus, Web of Science, Google Scholar, Pub-Med, and other literature databases. Several analytical techniques were employed during the development of the medicine to meet the qualitative and quantitative evaluation of efavirenz from diverse pharmaceutical and biological matrices. Analyzing the use of spectrophotometric and sophisticated chromatographic methods in the past and present to analyze efavirenz in biological samples and pharmaceutical formulations, either alone or in combination with other medications, is the main emphasis of this study's examination. Furthermore, it has been noted that the majority of EFV examination methods use high-performance liquid chromatography, both individually and together.